Benzinga·2026-02-17 12:04Core Insights - Teva and Sanofi announced positive results from the RELIEVE UCCD long-term extension study of duvakitug, showing durable clinical efficacy in ulcerative colitis and Crohn's disease patients over 44 weeks [1] Study Results - The study involved 130 patients who initially responded to duvakitug, with both doses (450 mg and 900 mg) being well tolerated [2] - In ulcerative colitis, 58% of patients on the 900 mg dose and 47% on the 450 mg dose achieved clinical remission [2] - In Crohn's disease, 55% of patients on the 900 mg dose and 41% on the 450 mg dose achieved endoscopic response [3] - Consistent benefits were observed across additional efficacy endpoints in both patient groups [3] Technical Analysis - The stock is currently trading 6.3% below its 20-day simple moving average and 10.5% below its 100-day simple moving average, indicating short-term weakness [4] - Over the past 12 months, shares have increased by 105.07% and are closer to their 52-week highs than lows [4] - The RSI is at 50.00, indicating neutral territory, while MACD is below its signal line, suggesting bearish pressure [4] Analyst Consensus & Recent Actions - The stock carries a Buy Rating with an average price target of $31.75 [5] - Recent analyst actions include Goldman Sachs raising the target to $45, Barclays raising the target to $38, and Scotiabank raising the target to $40 [5] - Teva shares are up 2.85% at $34.94 during premarket trading, while Sanofi shares are up 0.26% at $46.13 [5]